Zobrazeno 1 - 10
of 43
pro vyhledávání: '"TOMOHIRO OZAKI"'
Autor:
Takehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, Shunsuke Teraoka, Hiroshi Kobe, Koichi Azuma, Teppei Yamaguchi, Takeshi Masuda, Toshihide Yokoyama, Kohei Otsubo, Koji Haratani, Daisuke Hayakawa, Masahide Oki, Shinnosuke Takemoto, Tomohiro Ozaki, Yusaku Akashi, Akito Hata, Hiroya Hashimoto, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 23, Pp 21097-21110 (2023)
Abstract Background Actionable tumor genomic alterations, primarily EGFR mutations, occur in nearly 70% of Japanese advanced nonsquamous non‐small cell lung cancer (NSCLC) patients. Standard assessment of tumor tissue includes rapid testing for EGF
Externí odkaz:
https://doaj.org/article/653a72701e5d487b855668fed38c1519
Autor:
Kana Fujimoto, Satomi Watanabe, Yuto Yasuda, Emi Date, Yasuhiro Kawabata, Hiroaki Kanemura, Takayuki Takahama, Kimio Yonesaka, Norishige Iizuka, Ken‐ichi Takahashi, Osamu Kawakami, Tomohiro Ozaki, Kazuhiko Nakagawa
Publikováno v:
Thoracic Cancer, Vol 14, Iss 2, Pp 214-217 (2023)
Abstract High‐grade fetal lung adenocarcinoma (H‐FLAC) is a rare tumor, with little known of its response to chemotherapy with or without an immune checkpoint inhibitor or of its molecular profile. We report the first case of a 56‐year‐old ma
Externí odkaz:
https://doaj.org/article/3c35c62de9b54473a554522542d5f956
Autor:
Yasushi Goto, MD, PhD, Atsuhisa Tamura, MD, PhD, Hirotaka Matsumoto, MD, Kazutoshi Isobe, MD, PhD, Tomohiro Ozaki, MD, Melissa L. Santorelli, PhD, MPH, Kazuko Taniguchi, MS, Tetsu Kamitani, MD, PhD, Masato Irisawa, PhD, Kingo Kanda, MPharm, Machiko Abe, MS, Thomas Burke, PharmD, PhD, Hiroshi Nokihara, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100397- (2022)
Introduction: Pembrolizumab became available in Japan in February 2017 for first-line monotherapy of unresectable advanced and metastatic NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater than or equal to 50%. This ret
Externí odkaz:
https://doaj.org/article/6c1d51a111954179b8993ec6b3e61d62
Autor:
Ryoji Kato, Hidetoshi Hayashi, Eriko Miyawaki, Junichi Shimizu, Tomohiro Ozaki, Daichi Fujimoto, Ryo Toyozawa, Atsushi Nakamura, Toshiyuki Kozuki, Kentaro Tanaka, Shunsuke Teraoka, Kazuhiro Usui, Kazumi Nishino, Osamu Hataji, Keiichi Ota, Noriyuki Ebi, Sho Saeki, Yuki Akazawa, Motoyasu Okuno, Kazuhiko Nakagawa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundStudies have suggested that chemotherapy after immune checkpoint inhibitors may confer an improved response for non–small cell lung cancer (NSCLC). However, potential selection bias in such studies has not been addressed. We therefore app
Externí odkaz:
https://doaj.org/article/a1e05f97528e462ca8d6640b3c0bea4b
Publikováno v:
Mechanical Engineering Journal, Vol 4, Iss 6, Pp 16-00665-16-00665 (2017)
In automobile-exhaust systems, catalytic converters are the main components to produce substantial pressure drops, which induce engine-power loss and fuel-consumption rise. In addition to the need to reduce the pressure loss, the flow passing through
Externí odkaz:
https://doaj.org/article/2838d2bc688b426cb239e1d339d1eb23
Autor:
Kana Fujimoto, Satomi Watanabe, Yuto Yasuda, Emi Date, Yasuhiro Kawabata, Hiroaki Kanemura, Takayuki Takahama, Kimio Yonesaka, Norishige Iizuka, Ken‐ichi Takahashi, Osamu Kawakami, Tomohiro Ozaki, Kazuhiko Nakagawa
Publikováno v:
Thoracic Cancer. 14:214-217
Autor:
Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, Kenji Sawa, Yasuto Yoneshima, Ryota Saito, Tomohiro Ozaki, Kenjiro Tsuruoka, Akito Hata, Kosuke Tsuruno, Tomohiro Sakamoto, Shunsuke Teraoka, Masahide Oki, Hiroshi Watanabe, Tomoyuki Otani, Kazuko Sakai, Shuta Tomida, Yasutaka Chiba, Akihiko Ito, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Hidetoshi Hayashi
Publikováno v:
Cancer Research. 83:2173-2173
Background: Programmed cell death-ligand 1 (PD-L1) inhibitor durvalumab has been found to improve disease control in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with definitive concurrent chemoradiation therapy (dC
Autor:
Yusuke Kawanaka, Yuto Yasuda, Junko Tanizaki, Daisuke Iwashima, Yoshikane Nonagase, Kiyoshi Uemasu, Yutaka Hirayama, Masakazu Ogura, Tomohiro Ozaki, Ken-ichi Takahashi
Publikováno v:
Respiratory investigation. 60(5)
Some lung cancer patients have preexisting interstitial lung disease (ILD), which is considered a risk factor for lung cancer treatment. This study investigated the safety and efficacy of durvalumab consolidation therapy for patients with stage III n
Autor:
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, Makoto Nishio, Santiago Ponce Aix, Luis Paz-Ares, Chao-Hua Chiu, Keunchil Park, Silvia Novello, Ernest Nadal, Fumio Imamura, Kiyotaka Yoh, Jin-Yuan Shih, Kwok Hung Au, Denis Moro-Sibilot, Sotaro Enatsu, Annamaria Zimmermann, Bente Frimodt-Moller, Carla Visseren-Grul, Martin Reck, Quincy Chu, Alexis Cortot, Jean-Louis Pujol, Elizabeth Fabre, Corinne Lamour, Helge Bischoff, Jens Kollmeier, Martin Kimmich, Walburga Engel-Riedel, Stefan Hammerschmidt, Wolfgang Schütte, Konstantinos Syrigos, James Chung Man Ho, Kwok-Hung Au, Andrea Ardizzoni, Giulia Pasello, Vanessa Gregorc, Alessandro Del Conte, Domenico Galetta, Toshiaki Takahashi, Toru Kumagai, Katsuyuki Hotta, Yasushi Goto, Yukio Hosomi, Hiroshi Sakai, Yuichi Takiguchi, Young Hak Kim, Takayasu Kurata, Hiroyuki Yamaguchi, Haruko Daga, Isamu Okamoto, Miyako Satouchi, Satoshi Ikeda, Kazuo Kasahara, Shinji Atagi, Koichi Azuma, Keisuke Aoe, Yoshitsugu Horio, Nobuyuki Yamamoto, Hiroshi Tanaka, Satoshi Watanabe, Naoyuki Nogami, Tomohiro Ozaki, Ryo Koyama, Tomonori Hirashima, Hiroyasu Kaneda, Keisuke Tomii, Yuka Fujita, Masahiro Seike, Naoki Nishimura, Terufumi Kato, Masao Ichiki, Hideo Saka, Katsuya Hirano, Yasuharu Nakahara, Shunichi Sugawara, Sang-We Kim, Young Joo Min, Hyun Woo Lee, Jin-Hyoung Kang, Ho Jung An, Ki Hyeong Lee, Jin-Soo Kim, Gyeong-Won Lee, Sung Yong Lee, Aurelia Alexandru, Anghel Adrian Udrea, Óscar Juan-Vidal, Ernest Nadal-Alforja, Ignacio Gil-Bazo, Santiago Ponce-Aix, Belén Rubio-Viqueira, Miriam Alonso Garcia, Enriqueta Felip Font, Jose Fuentes Pradera, Juan Coves Sarto, Meng-Chih Lin, Wu-Chou Su, Te-Chun Hsia, Gee-Chen Chang, Yu-Feng Wei, Jian Su, Irfan Cicin, Tuncay Goksel, Hakan Harputluoglu, Ozgur Ozyilkan, Ivo Henning, Sanjay Popat, Olivia Hatcher, Kathryn Mileham, Jared Acoba, Edward Garon, Gabriel Jung, Moses Raj, William Martin, Shaker Dakhil
Publikováno v:
The Lancet Oncology. 20:1655-1669
Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the approach is not widely implemented. RELAY assessed erlotinib, an EGFR tyrosine kinase inh
Autor:
Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, Junko Tanizaki, Ryoji Kato, Seiichiro Mitani, Yusuke Kawanaka, Takashi Kurosaki, Yoshikazu Hasegawa, Takafumi Okabe, Kaoru Tanaka, Yusaku Akashi, Tomohiro Ozaki, Kazuto Nishio, Akihiko Ito, Kazuhiko Nakagawa
Publikováno v:
European journal of cancer (Oxford, England : 1990). 161
Tumour burden (TB) is implicated in resistance to programmed cell death-1/PD-L1 inhibitor (immune checkpoint inhibitor [ICI]) therapy. However, whether TB contributes to such resistance in non-small-cell lung cancer (NSCLC) has remained unknown.A tot